Putting Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia (AML) into Action

The PQI in Action incorporates opinions and experiences from oncology experts within the medically integrated teams at both The University of Minnesota Health (UM) in Minneapolis/ St. Paul as well as Rocky Mountain Cancer Centers (RMCC) throughout the state of Colorado. These two organizations are respected leaders in oncology and were selected based on their historic partnership and alignment with the NCODA Mission. Both cancer treatment centers have successfully implemented Medically Integrated Dispensing (MID) and the use of Positive Quality Interventions throughout their care teams to improve the clinical outcomes of patients receiving Xospata® (gilteritinib) for treatment of relapsed and/or refractory acute myeloid leukemia. who have mutations in the internal tandem duplication (ITD) and/or tyrosine kinase domain (TKD) of FLT3 (found in 30% of AML population).